Chemotherapy before surgery for potentially removable pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (mFOLFIRINOX) given before surgery to people with pancreatic cancer that may be removable. The goal is to see if this approach works well and to prepare for a larger study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with pancreatic cancer that is confirmed by a biopsy or similar test.
- Your cancer must be considered 'potentially resectable', meaning it may be possible to remove it with surgery (based on CT scan and review by a team of specialists).
- You should not have received chemotherapy before for this cancer.
- You must be 18 years or older.
- You must be in good general health (able to carry out daily activities) with blood counts and kidney function at acceptable levels.
- If you are a woman who could become pregnant, you will need a pregnancy test and must use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving treatment before surgery helps people with pancreatic cancer that can be removed. The treatment is given before the operation, and the study checks if it is safe and effective.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
Hear when a new Resectable Pancreatic Duct Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.